2023 World Conference on Lung Cancer (Posters)-EP07.01. Development of a Shared Decision-Making Tool for Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer.

EP07.01. Development of a Shared Decision-Making Tool for Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer. - PDF(Slides)

Back to course

Pdf Summary

Researchers at the Mayo Clinic in Rochester, MN have developed a shared decision-making tool for patients with resected non-small cell lung cancer (NSCLC) to help them make informed choices about adjuvant treatment. Adjuvant therapy after NSCLC surgery is crucial for improving clinical outcomes, and shared decision-making (SDM) facilitates communication between patients and clinicians to come up with the best treatment plan based on the patient's preferences. The decision aid supports discussions on systemic therapy options, survival risk approximation, potential harms, and practical considerations.<br /><br />A multidisciplinary team consisting of clinicians with expertise in NSCLC, SDM researchers, and design experts from Mayo Clinic implemented a human-centered design approach to develop the tool. This involved reviewing current evidence on chemotherapy, immunotherapy, and targeted therapy for adjuvant treatment, observing and analyzing usual practice, and developing a prototype of the decision aid. Clinical encounters where decisions about adjuvant treatment were expected to take place were observed via video recording to understand how patients and clinicians navigate through these decisions.<br /><br />The current version of the field-tested tool includes a risk calculator that depicts the patient's risk of dying within 5 years using a 100-person pictograph. It also provides information on various treatment options, such as chemotherapy, chemotherapy plus immunotherapy, targeted therapy, or monitoring, along with their respective benefits and side effects. The tool was easily adopted by providers and patients during the field testing phase.<br /><br />The decision aid is being updated with the latest FDA approval data, and a randomized trial is planned for further clinical testing. The tool aims to help physicians offer tailored estimates of the potential benefits, harms, and practical inconveniences of different treatment options. By providing high-quality, comprehensive, and up-to-date evidence, the decision aid promotes personalized treatment based on patient goals and priorities.

Asset Subtitle

Konstantinos Leventakos

Meta Tag

Speaker Konstantinos Leventakos

Topic Early-Stage NSCLC: Best Practice

Keywords

Mayo Clinic

shared decision-making

resected non-small cell lung cancer

adjuvant treatment

systemic therapy options

survival risk approximation

potential harms

practical considerations

human-centered design

risk calculator